Compare PNR & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNR | IONS |
|---|---|---|
| Founded | 1966 | 1989 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 11.9B |
| IPO Year | 2003 | 1996 |
| Metric | PNR | IONS |
|---|---|---|
| Price | $89.53 | $74.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 22 |
| Target Price | ★ $113.36 | $92.73 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | 5.88 | ★ 21.71 |
| EPS | ★ 3.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.24 | N/A |
| Revenue Next Year | $4.82 | $77.99 |
| P/E Ratio | $22.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $83.60 | $28.79 |
| 52 Week High | $113.95 | $86.74 |
| Indicator | PNR | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 48.81 |
| Support Level | $87.98 | $69.85 |
| Resistance Level | $91.13 | $77.08 |
| Average True Range (ATR) | 1.98 | 1.99 |
| MACD | 0.52 | 0.18 |
| Stochastic Oscillator | 66.99 | 49.24 |
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).